The treatment of advanced bladder cancer with sensitized pig lymphocytes

Abstract

Twenty‐five patients with transitional cell carcinoma of the urinary bladder have been treated by infusion of sensitized pig lymph node cells into the arterial blood supply of the tumour. In 7 cases pig cell infusion was the only treatment, in a further 7 patients pig cells were given in the treatment of a major tumour recurrence following radiotherapy and in 11 patients pig cell infusion was followed after 4‐8 weeks by an attenuated course of radiotherapy. In these three treatment groups 2, 3 and 9 patients respectively obtained clinical benefit and biopsy showed histological change.

The use of immunologically competent cells from pig mesenteric lymph nodes to treat pulmonary tumors in mice

“…Previous reports have described the use of cells from pig mesenteric lymph nodes, immunized against human urinary bladder carcinomata, in the treatment of these tumors (Symes et al, 1973;Feneley et al, 1974;Symes et al, 1978). In brief, fragments of tumor, obtained by transurethral resection, were implanted between the leaves of a pig mesentery.…”

Observations on the effect of radiotherapy, followed by injection of pig lymph node cells, in reducing the number of pulmonary tumors induced by intravenous injection of tumor cells into isogenic mice

“…Fourteen of 25 patients obtained clinical benefit as assessed by all of three parameters -a remission of symptoms, reduction in tumor size and histological change in the tumor (Symes et al, 1973;Feneley et al, 1974). These clinical observations raised a number of fundamental questions.…”

Adoptive immunotherapy for advanced cancer patients using in vitro activated cytotoxic T lymphocytes

“…Since Mitchison [1] first reported that allo-tumor rejection was mediated by immunized lymphocytes in 1955, many clinical trials to treat human cancers by means of adoptive transfer of lymphocytes have been conducted but with little or no clinical effect [2][3][4]. In 1985, Rosenberg et al [5] introduced lymphokineactivated killer cell therapy, and the reported clinical effects surprised many clinicians.…”